EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

New perspectives in cancer immunotherapy: targeting IL-6 cytokine family

Maria Florencia Soler iD, Andrea Abaurrea iD, Peio Azcoaga iD, Angela M Araujo iD, Maria M Caffarel iD

Journal for ImmunoTherapy of Cancer · 2023-11 · 11 (11) · e007530

DOI: 10.1136/jitc-2023-007530 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 09.11.2023. Verfasst von Maria Florencia Soler und 4 weiteren Autor:innen. Beteiligte Einrichtung: Biogipuzkoa (previously known as Biodonostia) Health Research Institute, Donostia-San Sebastian, Spain. Hauptthemen laut MEDLINE: Interleukin-6, Melanoma. Die Arbeit wurde bisher 198-mal zitiert (Crossref) und nennt 153 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Instituto de Salud Carlos III, Roche España, CIC biomaGUNE.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic inflammation has been recognized as a canonical cancer hallmark. It is orchestrated by cytokines, which are master regulators of the tumor microenvironment (TME) as they represent the main communication bridge between cancer cells, the tumor stroma, and the immune system. Interleukin (IL)-6 represents a keystone cytokine in the link between inflammation and cancer. Many cytokines from the IL-6 family, which includes IL-6, oncostatin M, leukemia inhibitory factor, IL-11, IL-27, IL-31, ciliary neurotrophic factor, cardiotrophin 1, and cardiotrophin-like cytokine factor 1, have been shown to elicit tumor-promoting roles by modulating the TME, making them attractive therapeutic targets for cancer treatment. The development of immune checkpoint blockade (ICB) immunotherapies has radically changed the outcome of some cancers including melanoma, lung, and renal, although not without hurdles. However, ICB shows limited efficacy in other solid tumors. Recent reports support that chronic inflammation and IL-6 cytokine signaling are involved in resistance to immunotherapy. This review summarizes the available preclinical and clinical data regarding the implication of IL-6-related cytokines in regulating the immune TME and the response to ICB. Moreover, the potential clinical benefit of combining ICB with therapies targeting IL-6 cytokine members for cancer treatment is discussed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin-6MelanomaHumansImmunotherapyInflammationTumor Microenvironment

Stichwörter der Autor:innen

CytokinesImmune Checkpoint InhibitorsImmunotherapyInflammation MediatorsTumor Microenvironment

Substanzen

Interleukin-6

Autor:innen und Institutionen

  • Biogipuzkoa (previously known as Biodonostia) Health Research Institute, Donostia-San Sebastian, Spain.
  • Biogipuzkoa (previously known as Biodonostia) Health Research Institute, Donostia-San Sebastian, Spain maria.munozcaffarel@biodonostia.org.
  • Ikerbasque Basque Foundation for Science, Bilbao, Spain.

ORCID-Profile: Maria Florencia Soler, Andrea Abaurrea, Peio Azcoaga, Angela M Araujo, Maria M Caffarel

Förderung

  • Instituto de Salud Carlos III
  • Roche España
  • CIC biomaGUNE
  • Abyntek Biopharma
  • Fundación Sociedad Española de Oncología Médica
  • Hezkuntza, Hizkuntza Politika Eta Kultura Saila, Eusko Jaurlaritza
  • Fundacion Gangoiti
  • Ikerbasque, Basque Foundation for Science

Zitieren

APA

Soler, M. F., Abaurrea, A., Azcoaga, P., Araujo, A. M., & Caffarel, M. M. (2023). New perspectives in cancer immunotherapy: targeting IL-6 cytokine family. Journal for ImmunoTherapy of Cancer, 11(11), e007530. https://doi.org/10.1136/jitc-2023-007530

Vancouver

Soler MF, Abaurrea A, Azcoaga P, Araujo AM, Caffarel MM. New perspectives in cancer immunotherapy: targeting IL-6 cytokine family. Journal for ImmunoTherapy of Cancer. 2023;11(11):e007530. doi:10.1136/jitc-2023-007530

BibTeX
@article{Soler2023,
  author = {Soler, Maria Florencia and Abaurrea, Andrea and Azcoaga, Peio and Araujo, Angela M and Caffarel, Maria M},
  title = {New perspectives in cancer immunotherapy: targeting IL-6 cytokine family},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2023},
  volume = {11},
  number = {11},
  pages = {e007530},
  doi = {10.1136/jitc-2023-007530}
}
Kostenlos starten →